---
document_datetime: 2025-12-29 13:37:07
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/cresemba.html
document_name: cresemba.html
version: success
processing_time: 0.1193619
conversion_datetime: 2025-12-30 02:26:22.700367
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Cresemba

[RSS](/en/individual-human-medicine.xml/66679)

##### Authorised

This medicine is authorised for use in the European Union

isavuconazole Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Cresemba](#news-on)
- [More information on Cresemba](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Cresemba is an antifungal medicine used to treat adults and children aged 1 year and older with invasive aspergillosis or mucormycosis (infections caused by fungi). For mucormycosis, Cresemba is used when another medicine, amphotericin B, is not suitable.

Invasive aspergillosis and mucormycosis are rare, and Cresemba was designated an 'orphan medicine' (a medicine used in rare diseases). Further information on the orphan designations can be found on the EMA website ( [mucormycosis](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1276) : 4 June 2014; [invasive aspergillosis](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1284) : 4 July 2014).

Cresemba contains the active substance isavuconazole.

Expand section

Collapse section

## How is Cresemba used?

Cresemba is available as a powder to make a solution for infusion (drip) given into a vein and as capsules to be taken by mouth. It is given once every 8 hours for the first 48 hours and then once a day. For children the dose and form depend on their bodyweight and age. The duration of treatment depends on how the patient responds to Cresemba.

For adults and children aged 6 years and older and weighing at least 16 kg, it is possible to switch between the infusion and the capsules, if needed.

Cresemba can only be obtained with a prescription. It should be used according to official recommendations on the appropriate use of antifungal medicines. For more information about using Cresemba, see the package leaflet or contact your doctor or pharmacist.

## How does Cresemba work?

The active substance in Cresemba, isavuconazole, belongs to the triazole class of antifungal medicines. It works by disrupting the formation of ergosterol, an important component of the fungal cell membranes (outer layers). Without a functional cell membrane, the fungus dies or cannot spread.

## What benefits of Cresemba have been shown in studies?

Studies have shown that survival of infected patients following treatment with Cresemba is similar to that seen with other antifungal treatments.

In a main study involving 516 adults with invasive aspergillosis, the proportion of people who died at 42 days was similar for those treated with Cresemba (19%) and those treated with another antifungal medicine called voriconazole (20%).

Another study involved 146 adults, 37 of whom had mucormycosis and were treated with Cresemba. Of these 37 patients, 43% died after 84 days, which is similar to rates seen in the published literature for standard treatments with amphotericin-B; Cresemba has the advantage that it can be used in patients with reduced kidney function.

The company also provided data from two studies involving a total of 77 children aged 1 to 18 years, 31 of whom had invasive aspergillosis or mucormycosis, and who were treated with Cresemba. The results showed that Cresemba behaves in the body in the same way in children as in adults.

## What are the risks associated with Cresemba?

For the full list of side effects and restrictions with Cresemba, see the package leaflet.

The most common side effects with Cresemba in adults (which may affect up to 1 in 10 people) include abnormal liver tests, nausea (feeling sick), vomiting, dyspnoea (difficulty breathing), abdominal (belly) pain, diarrhoea, injection site reactions, headache, hypokalaemia (low blood potassium) and skin rash.

The side effects with Cresemba when used in children are similar to those seen in adults.

Cresemba must not be used in patients who are taking any of the following:

- ketoconazole (an antifungal);
- high-dose ritonavir (an HIV medicine);
- certain medicines that increase the breakdown of isavuconazole in the body.

It must also not be used in patients with familial short QT syndrome, a heart rhythm problem.

## Why is Cresemba authorised in the EU?

Invasive aspergillosis and mucormycosis are life-threatening infections associated with high rates of death. At the time of authorisation there were few treatment options for adults with these infections, and even fewer for children.

In studies, Cresemba's effect was comparable to that of voriconazole in treating invasive aspergillosis. In the treatment of mucormycosis, the European Medicines Agency considered that Cresemba would benefit patients for whom amphotericin B, which is the first-line treatment for this infection, is not suitable. Studies in children show that Cresemba behaves in the same way as in adults. The medicine is therefore expected to also be effective in children aged 1 year and above with invasive aspergillosis or mucormycosis. Regarding safety, Cresemba was relatively well tolerated.

The Agency therefore decided that Cresemba's benefits are greater than its risks and that it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Cresemba?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Cresemba have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Cresemba are continuously monitored. Suspected side effects reported with Cresemba are carefully evaluated and any necessary action taken to protect patients.

## Other information about Cresemba

Cresemba received a marketing authorisation valid throughout the EU on 15 October 2015.

Cresemba : EPAR - Medicine overview

Reference Number: EMA/317020/2024

English (EN) (149.3 KB - PDF)

**First published:** 29/10/2015

**Last updated:** 01/10/2024

[View](/en/documents/overview/cresemba-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-937)

български (BG) (174.2 KB - PDF)

**First published:**

29/10/2015

**Last updated:**

01/10/2024

[View](/bg/documents/overview/cresemba-epar-medicine-overview_bg.pdf)

español (ES) (148.32 KB - PDF)

**First published:**

29/10/2015

**Last updated:**

01/10/2024

[View](/es/documents/overview/cresemba-epar-medicine-overview_es.pdf)

čeština (CS) (171.51 KB - PDF)

**First published:**

29/10/2015

**Last updated:**

01/10/2024

[View](/cs/documents/overview/cresemba-epar-medicine-overview_cs.pdf)

dansk (DA) (146.88 KB - PDF)

**First published:**

29/10/2015

**Last updated:**

01/10/2024

[View](/da/documents/overview/cresemba-epar-medicine-overview_da.pdf)

Deutsch (DE) (150.38 KB - PDF)

**First published:**

29/10/2015

**Last updated:**

01/10/2024

[View](/de/documents/overview/cresemba-epar-medicine-overview_de.pdf)

eesti keel (ET) (146.11 KB - PDF)

**First published:**

29/10/2015

**Last updated:**

01/10/2024

[View](/et/documents/overview/cresemba-epar-medicine-overview_et.pdf)

ελληνικά (EL) (172.45 KB - PDF)

**First published:**

29/10/2015

**Last updated:**

01/10/2024

[View](/el/documents/overview/cresemba-epar-medicine-overview_el.pdf)

français (FR) (149.64 KB - PDF)

**First published:**

29/10/2015

**Last updated:**

01/10/2024

[View](/fr/documents/overview/cresemba-epar-medicine-overview_fr.pdf)

hrvatski (HR) (169.77 KB - PDF)

**First published:**

29/10/2015

**Last updated:**

01/10/2024

[View](/hr/documents/overview/cresemba-epar-medicine-overview_hr.pdf)

italiano (IT) (147 KB - PDF)

**First published:**

29/10/2015

**Last updated:**

01/10/2024

[View](/it/documents/overview/cresemba-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (180.77 KB - PDF)

**First published:**

29/10/2015

**Last updated:**

01/10/2024

[View](/lv/documents/overview/cresemba-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (171.47 KB - PDF)

**First published:**

29/10/2015

**Last updated:**

01/10/2024

[View](/lt/documents/overview/cresemba-epar-medicine-overview_lt.pdf)

magyar (HU) (171.26 KB - PDF)

**First published:**

29/10/2015

**Last updated:**

01/10/2024

[View](/hu/documents/overview/cresemba-epar-medicine-overview_hu.pdf)

Malti (MT) (173.64 KB - PDF)

**First published:**

29/10/2015

**Last updated:**

01/10/2024

[View](/mt/documents/overview/cresemba-epar-medicine-overview_mt.pdf)

Nederlands (NL) (148.17 KB - PDF)

**First published:**

29/10/2015

**Last updated:**

01/10/2024

[View](/nl/documents/overview/cresemba-epar-medicine-overview_nl.pdf)

polski (PL) (171.49 KB - PDF)

**First published:**

29/10/2015

**Last updated:**

01/10/2024

[View](/pl/documents/overview/cresemba-epar-medicine-overview_pl.pdf)

português (PT) (148.93 KB - PDF)

**First published:**

29/10/2015

**Last updated:**

01/10/2024

[View](/pt/documents/overview/cresemba-epar-medicine-overview_pt.pdf)

română (RO) (169.71 KB - PDF)

**First published:**

29/10/2015

**Last updated:**

01/10/2024

[View](/ro/documents/overview/cresemba-epar-medicine-overview_ro.pdf)

slovenčina (SK) (170.54 KB - PDF)

**First published:**

29/10/2015

**Last updated:**

01/10/2024

[View](/sk/documents/overview/cresemba-epar-medicine-overview_sk.pdf)

slovenščina (SL) (168.35 KB - PDF)

**First published:**

29/10/2015

**Last updated:**

01/10/2024

[View](/sl/documents/overview/cresemba-epar-medicine-overview_sl.pdf)

Suomi (FI) (145.91 KB - PDF)

**First published:**

29/10/2015

**Last updated:**

01/10/2024

[View](/fi/documents/overview/cresemba-epar-medicine-overview_fi.pdf)

svenska (SV) (146.86 KB - PDF)

**First published:**

29/10/2015

**Last updated:**

01/10/2024

[View](/sv/documents/overview/cresemba-epar-medicine-overview_sv.pdf)

Cresemba : EPAR - Risk management plan

English (EN) (1.1 MB - PDF)

**First published:** 29/10/2015

**Last updated:** 01/10/2024

[View](/en/documents/rmp/cresemba-epar-risk-management-plan_en.pdf)

## Product information

Cresemba : EPAR - Product Information

English (EN) (1.26 MB - PDF)

**First published:** 17/01/2025

**Last updated:** 24/07/2025

[View](/en/documents/product-information/cresemba-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-165)

български (BG) (454.93 KB - PDF)

**First published:**

17/01/2025

**Last updated:**

24/07/2025

[View](/bg/documents/product-information/cresemba-epar-product-information_bg.pdf)

español (ES) (437.67 KB - PDF)

**First published:**

17/01/2025

**Last updated:**

24/07/2025

[View](/es/documents/product-information/cresemba-epar-product-information_es.pdf)

čeština (CS) (449.55 KB - PDF)

**First published:**

17/01/2025

**Last updated:**

24/07/2025

[View](/cs/documents/product-information/cresemba-epar-product-information_cs.pdf)

dansk (DA) (886.68 KB - PDF)

**First published:**

17/01/2025

**Last updated:**

24/07/2025

[View](/da/documents/product-information/cresemba-epar-product-information_da.pdf)

Deutsch (DE) (462.92 KB - PDF)

**First published:**

17/01/2025

**Last updated:**

24/07/2025

[View](/de/documents/product-information/cresemba-epar-product-information_de.pdf)

eesti keel (ET) (421.92 KB - PDF)

**First published:**

17/01/2025

**Last updated:**

24/07/2025

[View](/et/documents/product-information/cresemba-epar-product-information_et.pdf)

ελληνικά (EL) (476.99 KB - PDF)

**First published:**

17/01/2025

**Last updated:**

24/07/2025

[View](/el/documents/product-information/cresemba-epar-product-information_el.pdf)

français (FR) (458.99 KB - PDF)

**First published:**

17/01/2025

**Last updated:**

24/07/2025

[View](/fr/documents/product-information/cresemba-epar-product-information_fr.pdf)

hrvatski (HR) (464.92 KB - PDF)

**First published:**

17/01/2025

**Last updated:**

24/07/2025

[View](/hr/documents/product-information/cresemba-epar-product-information_hr.pdf)

íslenska (IS) (880.04 KB - PDF)

**First published:**

17/01/2025

**Last updated:**

24/07/2025

[View](/is/documents/product-information/cresemba-epar-product-information_is.pdf)

italiano (IT) (433.21 KB - PDF)

**First published:**

17/01/2025

**Last updated:**

24/07/2025

[View](/it/documents/product-information/cresemba-epar-product-information_it.pdf)

latviešu valoda (LV) (442.99 KB - PDF)

**First published:**

17/01/2025

**Last updated:**

24/07/2025

[View](/lv/documents/product-information/cresemba-epar-product-information_lv.pdf)

lietuvių kalba (LT) (432.62 KB - PDF)

**First published:**

17/01/2025

**Last updated:**

24/07/2025

[View](/lt/documents/product-information/cresemba-epar-product-information_lt.pdf)

magyar (HU) (460.02 KB - PDF)

**First published:**

17/01/2025

**Last updated:**

24/07/2025

[View](/hu/documents/product-information/cresemba-epar-product-information_hu.pdf)

Malti (MT) (500.27 KB - PDF)

**First published:**

17/01/2025

**Last updated:**

24/07/2025

[View](/mt/documents/product-information/cresemba-epar-product-information_mt.pdf)

Nederlands (NL) (438.74 KB - PDF)

**First published:**

17/01/2025

**Last updated:**

24/07/2025

[View](/nl/documents/product-information/cresemba-epar-product-information_nl.pdf)

norsk (NO) (904.53 KB - PDF)

**First published:**

17/01/2025

**Last updated:**

24/07/2025

[View](/no/documents/product-information/cresemba-epar-product-information_no.pdf)

polski (PL) (461.63 KB - PDF)

**First published:**

17/01/2025

**Last updated:**

24/07/2025

[View](/pl/documents/product-information/cresemba-epar-product-information_pl.pdf)

português (PT) (435.33 KB - PDF)

**First published:**

17/01/2025

**Last updated:**

24/07/2025

[View](/pt/documents/product-information/cresemba-epar-product-information_pt.pdf)

română (RO) (431.29 KB - PDF)

**First published:**

17/01/2025

**Last updated:**

24/07/2025

[View](/ro/documents/product-information/cresemba-epar-product-information_ro.pdf)

slovenčina (SK) (444.44 KB - PDF)

**First published:**

17/01/2025

**Last updated:**

24/07/2025

[View](/sk/documents/product-information/cresemba-epar-product-information_sk.pdf)

slovenščina (SL) (425.29 KB - PDF)

**First published:**

17/01/2025

**Last updated:**

24/07/2025

[View](/sl/documents/product-information/cresemba-epar-product-information_sl.pdf)

Suomi (FI) (768.77 KB - PDF)

**First published:**

17/01/2025

**Last updated:**

24/07/2025

[View](/fi/documents/product-information/cresemba-epar-product-information_fi.pdf)

svenska (SV) (873.14 KB - PDF)

**First published:**

17/01/2025

**Last updated:**

24/07/2025

[View](/sv/documents/product-information/cresemba-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** PSUSA/00010426/202409 17/07/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Cresemba : EPAR - All Authorised presentations

English (EN) (25.73 KB - PDF)

**First published:** 29/10/2015

**Last updated:** 01/10/2024

[View](/en/documents/all-authorised-presentations/cresemba-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-688)

български (BG) (28.61 KB - PDF)

**First published:**

29/10/2015

**Last updated:**

01/10/2024

[View](/bg/documents/all-authorised-presentations/cresemba-epar-all-authorised-presentations_bg.pdf)

español (ES) (25.2 KB - PDF)

**First published:**

29/10/2015

**Last updated:**

01/10/2024

[View](/es/documents/all-authorised-presentations/cresemba-epar-all-authorised-presentations_es.pdf)

čeština (CS) (27.08 KB - PDF)

**First published:**

29/10/2015

**Last updated:**

01/10/2024

[View](/cs/documents/all-authorised-presentations/cresemba-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (32.98 KB - PDF)

**First published:**

29/10/2015

**Last updated:**

01/10/2024

[View](/da/documents/all-authorised-presentations/cresemba-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (27.68 KB - PDF)

**First published:**

29/10/2015

**Last updated:**

01/10/2024

[View](/de/documents/all-authorised-presentations/cresemba-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (25.22 KB - PDF)

**First published:**

29/10/2015

**Last updated:**

01/10/2024

[View](/et/documents/all-authorised-presentations/cresemba-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (28.06 KB - PDF)

**First published:**

29/10/2015

**Last updated:**

01/10/2024

[View](/el/documents/all-authorised-presentations/cresemba-epar-all-authorised-presentations_el.pdf)

français (FR) (25.4 KB - PDF)

**First published:**

29/10/2015

**Last updated:**

01/10/2024

[View](/fr/documents/all-authorised-presentations/cresemba-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (25.82 KB - PDF)

**First published:**

29/10/2015

**Last updated:**

01/10/2024

[View](/hr/documents/all-authorised-presentations/cresemba-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (32.24 KB - PDF)

**First published:**

29/10/2015

**Last updated:**

01/10/2024

[View](/is/documents/all-authorised-presentations/cresemba-epar-all-authorised-presentations_is.pdf)

italiano (IT) (24.85 KB - PDF)

**First published:**

29/10/2015

**Last updated:**

01/10/2024

[View](/it/documents/all-authorised-presentations/cresemba-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (26.35 KB - PDF)

**First published:**

29/10/2015

**Last updated:**

01/10/2024

[View](/lv/documents/all-authorised-presentations/cresemba-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (26.51 KB - PDF)

**First published:**

29/10/2015

**Last updated:**

01/10/2024

[View](/lt/documents/all-authorised-presentations/cresemba-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (26.66 KB - PDF)

**First published:**

29/10/2015

**Last updated:**

01/10/2024

[View](/hu/documents/all-authorised-presentations/cresemba-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (26.64 KB - PDF)

**First published:**

29/10/2015

**Last updated:**

01/10/2024

[View](/mt/documents/all-authorised-presentations/cresemba-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (25.5 KB - PDF)

**First published:**

29/10/2015

**Last updated:**

01/10/2024

[View](/nl/documents/all-authorised-presentations/cresemba-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (32.09 KB - PDF)

**First published:**

29/10/2015

**Last updated:**

01/10/2024

[View](/no/documents/all-authorised-presentations/cresemba-epar-all-authorised-presentations_no.pdf)

polski (PL) (27.35 KB - PDF)

**First published:**

29/10/2015

**Last updated:**

01/10/2024

[View](/pl/documents/all-authorised-presentations/cresemba-epar-all-authorised-presentations_pl.pdf)

português (PT) (25.86 KB - PDF)

**First published:**

29/10/2015

**Last updated:**

01/10/2024

[View](/pt/documents/all-authorised-presentations/cresemba-epar-all-authorised-presentations_pt.pdf)

română (RO) (25.39 KB - PDF)

**First published:**

29/10/2015

**Last updated:**

01/10/2024

[View](/ro/documents/all-authorised-presentations/cresemba-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (27.25 KB - PDF)

**First published:**

29/10/2015

**Last updated:**

01/10/2024

[View](/sk/documents/all-authorised-presentations/cresemba-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (25.18 KB - PDF)

**First published:**

29/10/2015

**Last updated:**

01/10/2024

[View](/sl/documents/all-authorised-presentations/cresemba-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (30.95 KB - PDF)

**First published:**

29/10/2015

**Last updated:**

01/10/2024

[View](/fi/documents/all-authorised-presentations/cresemba-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (31.64 KB - PDF)

**First published:**

29/10/2015

**Last updated:**

01/10/2024

[View](/sv/documents/all-authorised-presentations/cresemba-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Cresemba Active substance isavuconazole International non-proprietary name (INN) or common name isavuconazole Therapeutic area (MeSH) Aspergillosis Anatomical therapeutic chemical (ATC) code J02AC05

### Pharmacotherapeutic group

- Antimycotics for systemic use
- Triazole derivatives

### Therapeutic indication

Powder for concentrate for solution for infusion:

Cresemba is indicated in patients from 1 year of age and older for the treatment of

- invasive aspergillosis
- mucormycosis in patients for whom amphotericin B is inappropriate (see sections 4.4 and 5.1)

Consideration should be given to official guidance on the appropriate use of antifungal agents.

Hard capsules:

Cresemba hard capsules are indicated in adults and in paediatric patients from 6 years of age for the treatment of

- invasive aspergillosis
- mucormycosis in patients for whom amphotericin B is inappropriate (see sections 4.4 and 5.1)

Consideration should be given to official guidance on the appropriate use of antifungal agents.

Cresemba 40 mg hard capsules are intended to be used for paediatric patients.

## Authorisation details

EMA product number EMEA/H/C/002734

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation holder

Basilea Pharmaceutica Deutschland GmbH

Marie-Curie-Strasse 8

Opinion adopted 23/07/2005 Marketing authorisation issued 15/10/2015 Revision 21

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Cresemba : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (217.73 KB - PDF)

**First published:** 24/07/2025

**Last updated:** 24/07/2025

[View](/en/documents/procedural-steps-after/cresemba-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Cresemba : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (214.37 KB - PDF)

**First published:** 23/02/2017

**Last updated:** 27/03/2025

[View](/en/documents/procedural-steps-after/cresemba-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Cresemba : EPAR - Statement indicating compliance with the agreed completed paediatric investigation plan

Reference Number: EMA/CHMP/298354/2024

English (EN) (126.18 KB - PDF)

**First published:** 11/09/2024

[View](/en/documents/pip-compliance/cresemba-epar-statement-indicating-compliance-agreed-completed-paediatric-investigation-plan_en.pdf)

Cresemba-H-C-002734-X-0042-G : EPAR - Assessment report

Adopted

Reference Number: EMA/330882/2024

English (EN) (976.83 KB - PDF)

**First published:** 11/09/2024

[View](/en/documents/variation-report/cresemba-h-c-002734-x-0042-g-epar-assessment-report_en.pdf)

CHMP post-authorisation summary of positive opinion for Cresemba (X-42-G)

Adopted

Reference Number: EMA/298353/2024

English (EN) (159.89 KB - PDF)

**First published:** 28/06/2024

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cresemba-x-42-g_en.pdf)

Cresemba-H-C-002734-P46-007 : EPAR - Assessment report

Reference Number: EMA/492925/2023

English (EN) (1.39 MB - PDF)

**First published:** 13/11/2023

[View](/en/documents/variation-report/cresemba-h-c-002734-p46-007-epar-assessment-report_en.pdf)

Cresemba-H-C-002734-P46-006 : EPAR - Assessment report

Adopted

Reference Number: EMA/CHMP/304783/2020

English (EN) (1.46 MB - PDF)

**First published:** 26/10/2023

[View](/en/documents/variation-report/cresemba-h-c-002734-p46-006-epar-assessment-report_en.pdf)

Cresemba-H-C-PSUSA-00010426-202109 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/669852/2022

English (EN) (100.68 KB - PDF)

**First published:** 29/07/2022

[View](/en/documents/scientific-discussion-variation/cresemba-h-c-psusa-00010426-202109-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Cresemba : EPAR - Public assessment report

Adopted

Reference Number: EMA/596950/2015

English (EN) (3.81 MB - PDF)

**First published:** 29/10/2015

**Last updated:** 29/10/2015

[View](/en/documents/assessment-report/cresemba-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Cresemba

Adopted

Reference Number: EMA/CHMP/470149/2015

English (EN) (71.85 KB - PDF)

**First published:** 24/07/2015

**Last updated:** 24/07/2015

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-cresemba_en.pdf)

#### News on Cresemba

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2024) 28/06/2024

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 July 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-july-2015) 24/07/2015

#### More information on Cresemba

- [EU/3/14/1276 - orphan designation for treatment of mucormycosis](/en/medicines/human/orphan-designations/eu-3-14-1276)
- [EU/3/14/1284 - orphan designation for treatment of invasive aspergillosis](/en/medicines/human/orphan-designations/eu-3-14-1284)
- [EMEA-001301-PIP02-12-M04 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001301-pip02-12-m04)
- [A non comparative , multi centre observational study: Isavuconazole (Cresemba) in Invasive Mould Infections (Invasive Aspergillosis, Invasive Mucormycosis) in India - post-authorisation study](https://catalogues.ema.europa.eu/study/48543)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 24/07/2025

## Share this page

[Back to top](#main-content)